---
title: 'Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL
  study'
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38830991/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240604181742&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: An unmet need exists for patients with relapsed/refractory (R/R) follicular
  lymphoma (FL) and high-risk disease features, such as progression of disease within
  24 months (POD24) from first-line immunochemotherapy or disease refractory to both
  CD20-targeting agent and alkylator (double refractory), due to no established standard
  of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an
  option in R/R FL after two or more lines of prior systemic therapy, but there is
  ...
disable_comments: true
---
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is ...